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ties or medications. This study aimed to determine the association of metabolic syn-
drome (MetS) and SGA use, and the incremental contributions of select psychiatric 
comorbidities and polypharmacy. METHODS: We applied descriptive and regression 
analyses to a large administrative claims database of antipsychotic users to examine 
the association between SGAs (aripiprazole, ziprasidone, risperidone, quetiapine, and 
olanzapine) and MetS, as well as the effects of psychiatric comorbidity and polyphar-
macy. Select psychiatric comorbidities included schizophrenia, bipolar, depression, 
and other psychiatric disorders. Psychiatric polypharmacy was deﬁ ned as concomitant 
use of antipsychotics with other psychiatric drugs with metabolic effects (selective 
serotonin reuptake inhibitors [SSRIs], tricyclic antidepressants [TCAs], other antide-
pressants, and mood stabilizers). RESULTS: Of 50,128 antipsychotic users, the preva-
lence of MetS was lower in SGA users than non-SGA users (7.6% vs. 12.8%; P < 
0.0001), who were older and had higher prevalence of MetS components. However, 
SGA users exhibited more indicators of psychiatric severity, as evidenced through 
higher prevalence of psychiatric disorders and higher concomitant use of other psy-
chiatric drugs. Multivariable regression analysis showed the odds of MetS was lower 
in SGA users (OR = 0.86; P < 0.001) than non-SGA users. Concomitant use of SSRIs 
and TCAs signiﬁ cantly increased the odds of having MetS (OR = 1.26 and 1.29, 
respectively), as did diagnoses of schizophrenia, bipolar or depression disorders (OR 
= 1.22, 1.18, 1.12, respectively) (all P < 0.001). CONCLUSIONS: Psychiatric comor-
bidity and polypharmacy signiﬁ cantly increase the odds of MetS in antipsychotic users. 
Findings demonstrate the need for practitioners to consider patients’ psychiatric 
comorbidity and polypharmacy burdens when prescribing SGAs. Results suggest that 
prescribers of SGAs may be aware of metabolic effects and therefore prescribe non-
SGAs to their more metabolically-vulnerable patients. Further research into the com-
plexities of treatment patterns and outcomes in this comorbid population is 
warranted. 
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OBJECTIVES: Early nonresponse to oral antipsychotics was previously shown to be 
a robust predictor of subsequent nonresponse to continued treatment with the same 
medication in the treatment of schizophrenia. This study assessed whether early 
response or early nonresponse to treatment can serve as a clinical marker in the treat-
ment of schizophrenia with an atypical antipsychotic in long-acting injection formula-
tion (depot). METHODS: This post hoc analysis used data (n = 233) from an 8-week 
randomized, double-blind placebo-controlled study of olanzapine long-acting injection 
(olanzapine-LAI) in the treatment of inpatients with schizophrenia. Early response to 
olanzapine-LAI was deﬁ ned as ≥30% improvement on the PANSS total score (scored 
0–6) from baseline to 4 weeks of treatment. Subsequent response was deﬁ ned as ≥40% 
improvement on the PANSS total score from baseline to endpoint. Predictive accuracy 
was assessed by calculating sensitivity, speciﬁ city, positive predictive value (PPV), 
negative predictive value (NPV), and overall predictive accuracy. Early responders and 
early non-responders to olanzapine-LAI were also compared on change in clinical and 
functional outcome measures. RESULTS: Early response/nonresponse to olanzapine-
LAI, assessed following 4 weeks of treatment, predicted subsequent response/nonre-
sponse with a high level of overall accuracy (79%), sensitivity (85%), speciﬁ city 
(72%), PPV (78%), and NPV (80%). Compared to early non-responders, early 
responders had signiﬁ cantly longer time to all-cause treatment discontinuation, greater 
symptom improvement at all time points (per PANSS total and subscale scores), and 
greater improvement in quality of life and level of social functioning (all at P ≥ 0.01). 
CONCLUSIONS: In this study of inpatients with schizophrenia, early response to 
olanzapine long-acting injection was found to be a robust predictor of subsequent 
response to the medication. Early responders experienced signiﬁ cantly better clinical 
and functional outcomes compared to early non-responders and had longer treatment 
duration. Current ﬁ ndings are consistent with previous research on oral antipsychotics 
and will require replication in future studies. 
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OBJECTIVES: Many studies have shown that the methadone maintenance treatment 
(MMT) can effectively and safely reduce heroin use. However, most studies only 
evaluated and compared drug treatment programs, but did not investigate the inﬂ u-
ence of area of treatment on individual behaviors and treatment outcome. This study, 
therefore, aimed to evaluate direct effects of area-level characteristics and interactive 
effects of area-level characteristics and individual characteristics on Methadone main-
tenance treatment, after considering individual-level characteristics in Taiwan. 
METHODS: All opioid-dependent persons from ﬁ ve hospitals in 2009 who were 
participating in the outpatient methadone maintenance program for the ﬁ rst time and 
met eligibility criteria were enrolled into the study. The impact of MMT on self–
perceived health status was assessed by the case manager of each hospital. Health 
status and treatment outcome were investigated at the ﬁ rst outpatient visit and at 
3-month follow-ups. Individual level and area level characteristics were also assessed. 
Multilevel linear models were used to estimate if the differences of quality of life and 
opioid treatment index before and after the MMT were signiﬁ cant. RESULTS: A total 
of 330 opioid-dependent patients were recruited in the study. During the follow-up 
period, 38% of participants completed study (N = 127). The mean age of study 
participants was 35 years. Most of participants were male, single, low education level, 
unemployed and smoking. Patients under MMT had statistically signiﬁ cant improve-
ments in total quality of life (t = −4.293, P < 0.000), opioid treatment index (OTI) (t 
= 8.44, P < 0.000), and the satisfaction of quality of life (t = −4.498, P < 0.000). 
Furthermore, our result indicated that the schizophrenic and older patients had sig-
niﬁ cantly poorer results. In addition, area of treatment was also signiﬁ cantly associ-
ated with OTI. CONCLUSIONS: MMT improves the quality of life of patients and 
reduce drug abuse problems. However, actions should be taken to minimize the varia-
tions among areas of treatment. 
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OBJECTIVES: This study aimed to estimate the withdrawal rate from the labor 
market among patients with schizophrenia or bipolar/depression in Taiwan. 
METHODS: The data source was the Psychiatric Inpatients Medical Claims Data 
(PIMC) from the National Health Research Institute (NHRI), Taiwan. The PIMC 
compiled all the health records during 1996–2008 for patients who had at least one 
psychiatric hospitalization during 1996–2001. The inclusion criteria were patients 
who: 1) had their initial psychiatric health record within 1998 to 2001; 2) had primary 
or secondary ICD-9-CM diagnosis of schizophrenia, bipolar or depression; 3) were 
under employment; and 4) were aged between 18 and 65. The ﬁ nal sample available 
for the analyses was 23,174 (11,970 for schizophrenia; 11,204 for bipolar/depression). 
An index date was created by subtracting 365 days from the date of initial health 
record for examining the impact of the disease on withdrawal pre and post of disease 
onset. To identify all withdrawal events, each case was tracked from the index date 
until December 31, 2008 or death, whichever came ﬁ rst. Women without events were 
censored on December 31, 2008. Kaplan–Meier method was used to estimate cumu-
lated employment rates. RESULTS: For patients with schizophrenia, withdrawal rate 
of 34% was found during 1 year before the disease onset. During 1 year before and 
one after the disease onset, the withdrawal rate increased to 52%. During 1 year before 
and 4 years after the disease onset, the rate raised to 78%. Similar patterns were 
observed for patients with bipolar/depression, with the corresponding rate equaling 
34%, 52%, and 75%. Median employment time (95% CI) was 672.0 days (645.0, 
698.0) for patients with schizophrenia, and 689.5 days (662.0 to 712.0) for patients 
with bipolar/depression. CONCLUSIONS: Schizophrenia, bipolar and depression 
were showed to have adverse impacts on labor participation. 
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OBJECTIVES: The aims of this study are to estimate the direct medical costs and 
utilization rate of psychiatric services among elder people (aged 65 and over) in 
Taiwan, and to evaluate the costs of the top ﬁ ve geriatric mental disorders. METHODS: 
This study was based on the National Health Insurance Research Database of Tai-
wan’s National Health Insurance (NHI) program. Detailed data was extracted from 
the Psychiatric Inpatient Medical Claim (PIMC) dataset. The PIMC included 96,013 
psychiatric inpatients’ data from 1996 to 2007. RESULTS: From 2002 through 2007, 
the sample included 15,109 (16% of all psychiatric inpatients) geropsychiatric inpa-
tients. The total admissions were 19,137 and the hospitalization rate was 1.27 per 
person per year. The average LOS (length of stay) was 35.05 days (acute bed), 78.71 
days (chronic bed), and average ambulatory visits were 9.48 per patient per year. The 
mean total hospital-related cost was USD 7.2 million and the mean cost for each 
patient was USD 2828 per year. The top ﬁ ve ranking mental disorders and their 
average costs per year were dementia (987 patients, USD 2.6 million), mood disorders 
(616, USD 1.6), schizophrenia (276, USD 1.0), other organic brain disorders (254, 
USD 0.6), and delusional disorders (149, USD 0.9). CONCLUSIONS: From 2002 
through 2007, the direct medical costs and utilization rate of psychiatric facilities by 
geropsychiatric inpatients increased annually in Taiwan. The direct medical costs of 
dementia, mood disorder and schizophrenia were signiﬁ cantly higher than those of 
the other mental disorders. The direct medical expenditures estimated in this study 
have implications for assessment of ﬁ nancial impact on future insurance budget plan-
ning in Taiwan. 
